Avalon GloboCare (ALBT) Competitors $3.73 -0.01 (-0.27%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. GDTC, CLNN, BCAB, CGTX, DARE, CVM, GRCE, CASI, EGRX, and OVIDShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include CytoMed Therapeutics (GDTC), Clene (CLNN), BioAtla (BCAB), Cognition Therapeutics (CGTX), Daré Bioscience (DARE), CEL-SCI (CVM), Grace Therapeutics (GRCE), CASI Pharmaceuticals (CASI), Eagle Pharmaceuticals (EGRX), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. CytoMed Therapeutics Clene BioAtla Cognition Therapeutics Daré Bioscience CEL-SCI Grace Therapeutics CASI Pharmaceuticals Eagle Pharmaceuticals Ovid Therapeutics Avalon GloboCare (NASDAQ:ALBT) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk, media sentiment and community ranking. Do analysts prefer ALBT or GDTC? CytoMed Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 110.97%. Given CytoMed Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytoMed Therapeutics is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ALBT or GDTC? Avalon GloboCare has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Does the media prefer ALBT or GDTC? In the previous week, Avalon GloboCare had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 4 mentions for Avalon GloboCare and 2 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.37 beat Avalon GloboCare's score of 0.22 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalon GloboCare 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, ALBT or GDTC? CytoMed Therapeutics has lower revenue, but higher earnings than Avalon GloboCare. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalon GloboCare$1.31M4.71-$16.71M-$19.96-0.19CytoMed TherapeuticsN/AN/A-$3.13MN/AN/A Do insiders and institutionals hold more shares of ALBT or GDTC? 1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 37.3% of Avalon GloboCare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ALBT or GDTC more profitable? CytoMed Therapeutics has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,125.59%. Company Net Margins Return on Equity Return on Assets Avalon GloboCare-1,125.59% N/A -73.69% CytoMed Therapeutics N/A N/A N/A Does the MarketBeat Community believe in ALBT or GDTC? CytoMed Therapeutics received 4 more outperform votes than Avalon GloboCare when rated by MarketBeat users. CompanyUnderperformOutperformAvalon GloboCareN/AN/ACytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo Votes SummaryCytoMed Therapeutics beats Avalon GloboCare on 8 of the 13 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.18M$3.00B$5.56B$7.83BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.1930.4222.4818.48Price / Sales4.71498.92394.56103.59Price / CashN/A168.6838.1834.62Price / Book-0.223.206.774.25Net Income-$16.71M-$72.35M$3.22B$248.23M7 Day Performance10.03%1.46%1.48%0.89%1 Month Performance-23.57%8.79%3.99%3.53%1 Year Performance-6.52%-22.36%16.15%5.08% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare0.953 of 5 stars$3.73-0.3%N/A-9.3%$6.18M$1.31M-0.195Short Interest ↑News CoverageGap UpGDTCCytoMed Therapeutics2.1512 of 5 stars$2.41+5.7%$5.00+107.5%+12.3%$26.37MN/A0.00N/AGap DownCLNNClene2.8313 of 5 stars$3.03+1.0%$50.20+1,556.8%-65.6%$26.05M$342,000.00-0.57100Upcoming EarningsBCABBioAtla2.8724 of 5 stars$0.44+1.0%$6.00+1,248.6%-78.4%$25.98M$11M-0.2660Upcoming EarningsNews CoverageCGTXCognition Therapeutics3.644 of 5 stars$0.42-4.9%$7.13+1,610.7%-77.6%$25.81MN/A-0.4320Upcoming EarningsShort Interest ↓News CoverageDAREDaré Bioscience2.2926 of 5 stars$2.89-3.0%$24.00+730.4%-20.1%$25.58M$9,784.00-4.8930Short Interest ↓Positive NewsCVMCEL-SCIN/A$0.30+4.6%N/A-80.1%$25.57MN/A-0.6343Analyst ForecastGRCEGrace Therapeutics2.3935 of 5 stars$2.51+0.8%$12.00+378.1%N/A$25.45MN/A-2.16N/APositive NewsGap DownCASICASI Pharmaceuticals3.8381 of 5 stars$2.03-1.0%$4.00+97.0%-15.7%$24.97M$28.54M-0.91180Analyst ForecastEGRXEagle PharmaceuticalsN/A$1.92+12.9%N/A-52.1%$24.94M$257.55M0.00100Analyst ForecastGap DownOVIDOvid Therapeutics4.4359 of 5 stars$0.35+0.9%$3.03+766.7%-89.3%$24.88M$566,000.00-0.7460Gap Down Related Companies and Tools Related Companies CytoMed Therapeutics Competitors Clene Competitors BioAtla Competitors Cognition Therapeutics Competitors Daré Bioscience Competitors CEL-SCI Competitors Grace Therapeutics Competitors CASI Pharmaceuticals Competitors Eagle Pharmaceuticals Competitors Ovid Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALBT Stock Free ALBT Stock Alerts